Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.

Linehan WM, Ricketts CJ.

Nat Rev Urol. 2019 Sep;16(9):539-552. doi: 10.1038/s41585-019-0211-5. Epub 2019 Jul 5. Review.

PMID:
31278395
2.

The Metabolic Basis of Kidney Cancer.

Linehan WM, Schmidt LS, Crooks DR, Wei D, Srinivasan R, Lang M, Ricketts CJ.

Cancer Discov. 2019 Aug;9(8):1006-1021. doi: 10.1158/2159-8290.CD-18-1354. Epub 2019 May 14. Review.

PMID:
31088840
3.

Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease.

Wu J, Wang H, Ricketts CJ, Yang Y, Merino MJ, Zhang H, Shi G, Gan H, Linehan WM, Zhu Y, Ye D.

Cancer. 2019 Apr 1;125(7):1060-1069. doi: 10.1002/cncr.31908. Epub 2018 Dec 12.

PMID:
30548481
4.

CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors.

Vocke CD, Ricketts CJ, Ball MW, Schmidt LS, Metwalli AR, Middelton LA, Killian JK, Khan J, Meltzer PS, Simonds WF, Merino MJ, Linehan WM.

Urology. 2019 Feb;124:91-97. doi: 10.1016/j.urology.2018.11.013. Epub 2018 Nov 16.

5.

Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma.

Hsieh JJ, Le VH, Oyama T, Ricketts CJ, Ho TH, Cheng EH.

J Clin Oncol. 2018 Oct 29:JCO2018792549. doi: 10.1200/JCO.2018.79.2549. [Epub ahead of print]

PMID:
30372397
6.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM.

Cell Rep. 2018 Jun 19;23(12):3698. doi: 10.1016/j.celrep.2018.06.032. No abstract available.

7.

The origin, evolution and route to metastasis of clear cell RCC.

Ricketts CJ, Linehan WM.

Nat Rev Nephrol. 2018 Sep;14(9):538-540. doi: 10.1038/s41581-018-0031-5. No abstract available.

PMID:
29875480
8.

Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma.

Ricketts CJ, Linehan WM.

Cell. 2018 Apr 19;173(3):540-542. doi: 10.1016/j.cell.2018.03.077.

9.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM.

Cell Rep. 2018 Apr 3;23(1):313-326.e5. doi: 10.1016/j.celrep.2018.03.075. Erratum in: Cell Rep. 2018 Jun 19;23(12):3698.

10.

Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers.

Sourbier C, Liao PJ, Ricketts CJ, Wei D, Yang Y, Baranes SM, Gibbs BK, Ohanjanian L, Spencer Krane L, Scroggins BT, Keith Killian J, Wei MH, Kijima T, Meltzer PS, Citrin DE, Neckers L, Vocke CD, Marston Linehan W.

Oncotarget. 2018 Jan 10;9(12):10723-10733. doi: 10.18632/oncotarget.24112. eCollection 2018 Feb 13.

11.

Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma.

Ricketts CJ, Linehan WM.

Cancer Discov. 2017 Nov;7(11):1221-1223. doi: 10.1158/2159-8290.CD-17-0971.

12.

Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276).

Yang Y, Vocke CD, Ricketts CJ, Wei D, Padilla-Nash HM, Lang M, Sourbier C, Killian JK, Boyle SL, Worrell R, Meltzer PS, Ried T, Merino MJ, Metwalli AR, Linehan WM.

Genes Chromosomes Cancer. 2017 Oct;56(10):719-729. doi: 10.1002/gcc.22476. Epub 2017 Jul 24.

13.

Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma.

Vocke CD, Ricketts CJ, Merino MJ, Srinivasan R, Metwalli AR, Middelton LA, Peterson J, Yang Y, Linehan WM.

Genes Chromosomes Cancer. 2017 Jun;56(6):484-492. doi: 10.1002/gcc.22452. Epub 2017 Mar 31.

14.

Kidney cancer in 2016: RCC - advances in targeted therapeutics and genomics.

Linehan WM, Ricketts CJ.

Nat Rev Urol. 2017 Feb;14(2):76-78. doi: 10.1038/nrurol.2016.260. Epub 2016 Dec 29. Review. No abstract available.

PMID:
28031562
15.

Targeting HIF2α in Clear-Cell Renal Cell Carcinoma.

Ricketts CJ, Crooks DR, Linehan WM.

Cancer Cell. 2016 Oct 10;30(4):515-517. doi: 10.1016/j.ccell.2016.09.016.

16.

Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation.

Peri S, Caretti E, Tricarico R, Devarajan K, Cheung M, Sementino E, Menges CW, Nicolas E, Vanderveer LA, Howard S, Conrad P, Crowell JA, Campbell KS, Ross EA, Godwin AK, Yeung AT, Clapper ML, Uzzo RG, Henske EP, Ricketts CJ, Vocke CD, Linehan WM, Testa JR, Bellacosa A, Kopelovich L, Knudson AG.

Oncotarget. 2017 Mar 14;8(11):17628-17642. doi: 10.18632/oncotarget.12192.

17.

Papillary Renal-Cell Carcinoma.

Linehan WM, Merino MJ, Ricketts CJ.

N Engl J Med. 2016 May 19;374(20):1991. doi: 10.1056/NEJMc1601872. No abstract available.

PMID:
27192682
18.

Patient-specific factors influence somatic variation patterns in von Hippel-Lindau disease renal tumours.

Fei SS, Mitchell AD, Heskett MB, Vocke CD, Ricketts CJ, Peto M, Wang NJ, Sönmez K, Linehan WM, Spellman PT.

Nat Commun. 2016 May 13;7:11588. doi: 10.1038/ncomms11588.

19.

SnapShot: Renal Cell Carcinoma.

Ricketts CJ, Crooks DR, Sourbier C, Schmidt LS, Srinivasan R, Linehan WM.

Cancer Cell. 2016 Apr 11;29(4):610-610.e1. doi: 10.1016/j.ccell.2016.03.021.

20.

SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery.

Saxena N, Maio N, Crooks DR, Ricketts CJ, Yang Y, Wei MH, Fan TW, Lane AN, Sourbier C, Singh A, Killian JK, Meltzer PS, Vocke CD, Rouault TA, Linehan WM.

J Natl Cancer Inst. 2016 Jan;108(1). doi: 10.1093/jnci/djv287.

21.

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R.

N Engl J Med. 2016 Jan 14;374(2):135-45. doi: 10.1056/NEJMoa1505917. Epub 2015 Nov 4.

22.

Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC).

Ricketts CJ, Linehan WM.

PLoS One. 2015 Oct 20;10(10):e0140257. doi: 10.1371/journal.pone.0140257. eCollection 2015.

23.

New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.

Srinivasan R, Ricketts CJ, Sourbier C, Linehan WM.

Clin Cancer Res. 2015 Jan 1;21(1):10-7. doi: 10.1158/1078-0432.CCR-13-2993.

24.

Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer.

Sourbier C, Ricketts CJ, Matsumoto S, Crooks DR, Liao PJ, Mannes PZ, Yang Y, Wei MH, Srivastava G, Ghosh S, Chen V, Vocke CD, Merino M, Srinivasan R, Krishna MC, Mitchell JB, Pendergast AM, Rouault TA, Neckers L, Linehan WM.

Cancer Cell. 2014 Dec 8;26(6):840-850. doi: 10.1016/j.ccell.2014.10.005.

25.

Decade in review-kidney cancer: discoveries, therapies and opportunities.

Linehan WM, Ricketts CJ.

Nat Rev Urol. 2014 Nov;11(11):614-6. doi: 10.1038/nrurol.2014.262. Epub 2014 Oct 7. No abstract available.

26.

The somatic genomic landscape of chromophobe renal cell carcinoma.

Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA; The Cancer Genome Atlas Research Network, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ.

Cancer Cell. 2014 Sep 8;26(3):319-330. doi: 10.1016/j.ccr.2014.07.014. Epub 2014 Aug 21.

27.

Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers.

Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, Srinivasan R, Linehan WM.

Nat Rev Urol. 2014 Aug;11(8):465-75. doi: 10.1038/nrurol.2014.162. Epub 2014 Jul 22. Review.

28.

Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer.

Shuch B, Agochukwu N, Ricketts CJ, Vocke CD, Gautam R, Merino M, Linehan WM, Srinivasan R.

J Clin Oncol. 2016 Mar 20;34(9):e76-9. doi: 10.1200/JCO.2013.51.0214. Epub 2014 Jul 14. No abstract available.

PMID:
25024072
29.

Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas.

Hill VK, Shinawi T, Ricketts CJ, Krex D, Schackert G, Bauer J, Wei W, Cruickshank G, Maher ER, Latif F.

BMC Cancer. 2014 Jul 10;14:506. doi: 10.1186/1471-2407-14-506.

30.

The genetic basis of pheochromocytoma and paraganglioma: implications for management.

Shuch B, Ricketts CJ, Metwalli AR, Pacak K, Linehan WM.

Urology. 2014 Jun;83(6):1225-32. doi: 10.1016/j.urology.2014.01.007. Epub 2014 Mar 15. Review.

31.

Intratumoral heterogeneity in kidney cancer.

Ricketts CJ, Linehan WM.

Nat Genet. 2014 Mar;46(3):214-5. doi: 10.1038/ng.2904.

32.
33.

Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management.

Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metwalli AR, Srinivasan R, Linehan WM.

J Clin Oncol. 2014 Feb 10;32(5):431-7. doi: 10.1200/JCO.2013.50.8192. Epub 2013 Dec 30.

34.

The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function.

Qin Y, Deng Y, Ricketts CJ, Srikantan S, Wang E, Maher ER, Dahia PL.

Hum Mol Genet. 2014 May 1;23(9):2428-39. doi: 10.1093/hmg/ddt638. Epub 2013 Dec 13.

35.

Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma.

Ricketts CJ, Morris MR, Gentle D, Shuib S, Brown M, Clarke N, Wei W, Nathan P, Latif F, Maher ER.

Clin Epigenetics. 2013 Sep 13;5(1):16. doi: 10.1186/1868-7083-5-16.

36.

UBE2QL1 is disrupted by a constitutional translocation associated with renal tumor predisposition and is a novel candidate renal tumor suppressor gene.

Wake NC, Ricketts CJ, Morris MR, Prigmore E, Gribble SM, Skytte AB, Brown M, Clarke N, Banks RE, Hodgson S, Turnell AS, Maher ER, Woodward ER.

Hum Mutat. 2013 Dec;34(12):1650-61. doi: 10.1002/humu.22433. Epub 2013 Oct 7.

37.

New insights into von Hippel-Lindau function highlighted by investigation of the trichloroethylene-induced p.P81S hotspot mutation.

Neckers L, Ricketts CJ, Marston Linehan W.

J Natl Cancer Inst. 2013 Sep 18;105(18):1339-40. doi: 10.1093/jnci/djt240. Epub 2013 Aug 29. No abstract available.

38.

Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma.

Yang Y, Lane AN, Ricketts CJ, Sourbier C, Wei MH, Shuch B, Pike L, Wu M, Rouault TA, Boros LG, Fan TW, Linehan WM.

PLoS One. 2013 Aug 15;8(8):e72179. doi: 10.1371/journal.pone.0072179. eCollection 2013.

39.

Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer.

Shuch B, Ricketts CJ, Vocke CD, Komiya T, Middelton LA, Kauffman EC, Merino MJ, Metwalli AR, Dennis P, Linehan WM.

J Urol. 2013 Dec;190(6):1990-8. doi: 10.1016/j.juro.2013.06.012. Epub 2013 Jun 11.

40.

A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.

Farley MN, Schmidt LS, Mester JL, Pena-Llopis S, Pavia-Jimenez A, Christie A, Vocke CD, Ricketts CJ, Peterson J, Middelton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie XJ, Dahia PLM, Eng C, Linehan WM, Brugarolas J.

Mol Cancer Res. 2013 Sep;11(9):1061-1071. doi: 10.1158/1541-7786.MCR-13-0111. Epub 2013 May 24.

41.

Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.

Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, Yang Y, Wei MH, Pautler SE, Peterson J, Stolle CA, Zbar B, Merino MJ, Schmidt LS, Pinto PA, Srinivasan R, Pacak K, Linehan WM.

J Urol. 2012 Dec;188(6):2063-71. doi: 10.1016/j.juro.2012.08.030. Epub 2012 Oct 18.

42.

Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer.

Shuch B, Ricketts CJ, Vocke CD, Valera VA, Chen CC, Gautam R, Gupta GN, Gomez Macias GS, Merino MJ, Bratslavsky G, Linehan WM.

J Urol. 2013 Feb;189(2):430-5. doi: 10.1016/j.juro.2012.07.139. Epub 2012 Sep 19.

43.

A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer.

Yang Y, Valera V, Sourbier C, Vocke CD, Wei M, Pike L, Huang Y, Merino MA, Bratslavsky G, Wu M, Ricketts CJ, Linehan WM.

Cancer Genet. 2012 Jul-Aug;205(7-8):377-90. doi: 10.1016/j.cancergen.2012.05.001.

44.

The metabolic basis of kidney cancer.

Linehan WM, Ricketts CJ.

Semin Cancer Biol. 2013 Feb;23(1):46-55. doi: 10.1016/j.semcancer.2012.06.002. Epub 2012 Jun 13. Review.

45.

Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma.

Ricketts CJ, Morris MR, Gentle D, Brown M, Wake N, Woodward ER, Clarke N, Latif F, Maher ER.

Epigenetics. 2012 Mar;7(3):278-90. doi: 10.4161/epi.7.3.19103.

46.

Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility.

Astuti D, Morris MR, Cooper WN, Staals RH, Wake NC, Fews GA, Gill H, Gentle D, Shuib S, Ricketts CJ, Cole T, van Essen AJ, van Lingen RA, Neri G, Opitz JM, Rump P, Stolte-Dijkstra I, Müller F, Pruijn GJ, Latif F, Maher ER.

Nat Genet. 2012 Feb 5;44(3):277-84. doi: 10.1038/ng.1071.

PMID:
22306653
47.

Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas.

Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Pérez L, King EE, Toledo RA, Ercolino T, Rapizzi E, Ricketts CJ, Mori L, Giacchè M, Mendola A, Taschin E, Boaretto F, Loli P, Iacobone M, Rossi GP, Biondi B, Lima-Junior JV, Kater CE, Bex M, Vikkula M, Grossman AB, Gruber SB, Barontini M, Persu A, Castellano M, Toledo SP, Maher ER, Mannelli M, Opocher G, Robledo M, Dahia PL.

JAMA. 2010 Dec 15;304(23):2611-9. doi: 10.1001/jama.2010.1830.

PMID:
21156949
48.

Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma.

Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, Brown M, Kishida T, Yao M, Banks RE, Clarke N, Latif F, Maher ER.

Oncogene. 2011 Mar 24;30(12):1390-401. doi: 10.1038/onc.2010.525. Epub 2010 Dec 6.

PMID:
21132003
49.

Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility.

Astuti D, Ricketts CJ, Chowdhury R, McDonough MA, Gentle D, Kirby G, Schlisio S, Kenchappa RS, Carter BD, Kaelin WG Jr, Ratcliffe PJ, Schofield CJ, Latif F, Maher ER.

Endocr Relat Cancer. 2010 Dec 21;18(1):73-83. doi: 10.1677/ERC-10-0113. Print 2011 Feb.

50.

Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.

Morris MR, Hughes DJ, Tian YM, Ricketts CJ, Lau KW, Gentle D, Shuib S, Serrano-Fernandez P, Lubinski J, Wiesener MS, Pugh CW, Latif F, Ratcliffe PJ, Maher ER.

Anticancer Res. 2009 Nov;29(11):4337-43.

Supplemental Content

Loading ...
Support Center